Cynapsus Therapeutics Inc., of Toronto, said it is initiating phase II studies for APL-130277, a fast-acting reformulation of apomorphine, in Parkinson's disease (PD) following guidance from the FDA. Study CTH-105 will be conducted according to the proposal submitted to the FDA under the company´s investigational new drug application.